Metastatic Hormone Refractory Prostate Cancer Pipeline Expands as 180+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight's "Metastatic Hormone Refractory Prostate Cancer Pipeline Insight 2026" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Metastatic Hormone Refractory Prostate Cancer pipeline landscape. It covers the Metastatic Hormone Refractory Prostate Cancer Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Hormone Refractory Prostate Cancer Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Metastatic Hormone Refractory Prostate Cancer Pipeline? @ https://www.delveinsight.com/sample-request/metastatic-hormone-refractory-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Metastatic Hormone Refractory Prostate Cancer Pipeline Report
• On July 29, 2026- Pfizer highlighted a phase 3 study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
• On July 24, 2026- Amgen initiated a phase 3 study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
• On July 23, 2026- ORIC Pharmaceuticals announced a phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamide) or docetaxel for treating patients with metastatic castration resistant prostate cancer (mCRPC) who were previously treated with abiraterone acetate.
• On July 22, 2026- Celgene conducted a phase 3 study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of BMS-986365 versus investigator's choice comprising Docetaxel + Prednisone/Prednisolone or Abiraterone + Prednisone/Prednisolone or Enzalutamide.
• DelveInsight's Metastatic Hormone Refractory Prostate Cancer Pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Metastatic Hormone Refractory Prostate Cancer treatment.
• The leading Metastatic Hormone Refractory Prostate Cancer Companies such as Lantheus, Merck, Exelixis, Zenith Epigenetics, CellCentric, Karyopharm Therapeutics, Janux Therapeutics, Pfizer, Tavanta Therapeutics, Telix Pharmaceuticals, Jiangsu HengRui Medicine, SOTIO, Antev Ltd., Syntrix Pharmaceuticals, Regeneron Pharmaceuticals, Madison Vaccines, Phosplatin Therapeutics, MacroGenics, RedHill Biopharma, Xencor and others.
• Promising Metastatic Hormone Refractory Prostate Cancer Therapies such as Enzalutamide, Patupilone, Prednisone, Docetaxel, Zactima (vandetanib), MDX-010, Denosumab, and others.

Want to know which companies are leading innovation in Metastatic Hormone Refractory Prostate Cancer? @ https://www.delveinsight.com/sample-request/metastatic-hormone-refractory-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

The Metastatic Hormone Refractory Prostate Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Metastatic Hormone Refractory Prostate Cancer Pipeline Report also highlights the unmet needs with respect to the Metastatic Hormone Refractory Prostate Cancer.

Metastatic Hormone Refractory Prostate Cancer Overview
Metastatic Hormone-Refractory Prostate Cancer (mHRPC), also known as metastatic castration-resistant prostate cancer (mCRPC), is an advanced stage of prostate cancer in which the disease continues to progress despite the suppression of castrate levels. Initially, prostate cancer growth is typically driven by androgens, and hormone therapy is effective in slowing or stopping the disease. However, in mHRPC, cancer cells adapt and continue to grow even in the low-androgen environment. The cancer has also spread beyond the prostate gland to distant sites, most commonly bones and lymph nodes. This stage is associated with more aggressive behavior, increased symptom burden, and limited treatment options, requiring systemic therapies aimed at prolonging survival and improving quality of life.

Metastatic Hormone Refractory Prostate Cancer Emerging Drugs Profile
• PNT2002: Lantheus
A radioconjugate composed of PNT2002, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity. Upon administration of lutetium Lu-177 PNT2002, the PNT2002 moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells. The FDA has also granted fast track designation to the prostate specific membrane antigen (PSMA)-targeted therapy, 177Lu-PNT2002, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Currently, the drug is in Phase III stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

• Opevesostat: Merck
Opevesostat is an oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as prostate cancer. By inhibiting CYP11A1 enzyme activity, ODM-208 is designed to suppress the production of all steroid hormones and their precursors that may activate the androgen receptor signaling pathway. . Currently, the drug is in Phase III stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

• XL092: Exelixis
XL092 is a next-generation oral TKI that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and resistance to multiple therapies, including immune checkpoint inhibitors. XL092 is currently being developed for the treatment of advanced solid tumors, including genitourinary cancers, as a monotherapy and in combination with immune checkpoint inhibitors. Currently, the drug is in Phase II stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

• ZEN 3694: Zenith Epigenetics
ZEN-3694 is an orally bioavailable, potent, small molecule BET inhibitor that selectively binds to both bromodomains of the BET proteins. The drug candidate was discovered and developed from a BET bromodomain inhibitor platform. Bromodomain and Extra-Terminal domain (BET) family of proteins (BRD2, BRD3, BRD4, and BRDT) can bind acetylated lysines through their tandem bromodomains to promote gene transcription. BET bromodomain inhibitors (BETi) target super enhancers and inhibit several programs involved in tumorigenesis such as proliferation, metastasis, invasion, and immune evasion. Currently, the drug is in Phase II stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

• CCS1477: CellCentric
Inobrodib is a small molecule inhibitor, taken orally as a capsule. It inhibits p300 and CBP through binding into the conserved bromodomain of the twin proteins. This impacts the expression of key cancer drivers, including MYC and IRF4. Different cancer indications can be targeted by inobrodib as monotherapy or in combination with existing standard of care drugs. Currently, the drug is in Phase I/II stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

• KPT-8602: Karyopharm Therapeutics
Eltanexor (KPT-8602) is a second generation oral SINE compound. Eltanexor functions by binding to and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus. Eltanexor has demonstrated minimal brain penetration in animals, which has been associated with reduced toxicities in preclinical studies while maintaining potent anti-tumor effects. Currently, the drug is in Phase I/II stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

• JANX 007: Janux Therapeutics
JANX007 is lead novel Tumor Activated T Cell Engager (TRACTr). JANX007 is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of tumors and is in the clinic for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The company designed PSMA-TRACTr drug candidate as a single-masked TRACTr in which the PSMA-binding domain is unmasked. The T cell-specific binding domain (CD3e) is masked to help minimize CRS. Currently, the drug is in Phase I stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

• PF07248144: Pfizer
PF-07248144, developed by Pfizer, is a small molecule antineoplastic agent that functions as a histone acetyltransferase (HAT) inhibitor. By inhibiting HAT, it potentially disrupts gene expression and cellular processes that promote cancer growth. Its mechanism of action targets the modification of histones, a key process in epigenetic regulation. Currently, the drug is in Phase I stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

If you're tracking ongoing Metastatic Hormone Refractory Prostate Cancer Clinical trials @ https://www.delveinsight.com/sample-request/metastatic-hormone-refractory-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

The Metastatic Hormone Refractory Prostate Cancer Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Hormone Refractory Prostate Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Hormone Refractory Prostate Cancer Treatment.
• Metastatic Hormone Refractory Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Hormone Refractory Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Hormone Refractory Prostate Cancer market.

Metastatic Hormone Refractory Prostate Cancer Companies
Lantheus, Merck, Exelixis, Zenith Epigenetics, CellCentric, Karyopharm Therapeutics, Janux Therapeutics, Pfizer, Tavanta Therapeutics, Telix Pharmaceuticals, Jiangsu HengRui Medicine, SOTIO, Antev Ltd., Syntrix Pharmaceuticals, Regeneron Pharmaceuticals, Madison Vaccines, Phosplatin Therapeutics, MacroGenics, RedHill Biopharma, Xencor and others.

Metastatic Hormone Refractory Prostate Cancer Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Metastatic Hormone Refractory Prostate Cancer Products have been categorized under various Molecule types such as,
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Metastatic Hormone Refractory Prostate Cancer Pipeline Report @ https://www.delveinsight.com/sample-request/metastatic-hormone-refractory-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Metastatic Hormone Refractory Prostate Cancer Pipeline Report
• Coverage- Global
• Metastatic Hormone Refractory Prostate Cancer Companies- Lantheus, Merck, Exelixis, Zenith Epigenetics, CellCentric, Karyopharm Therapeutics, Janux Therapeutics, Pfizer, Tavanta Therapeutics, Telix Pharmaceuticals, Jiangsu HengRui Medicine, SOTIO, Antev Ltd., Syntrix Pharmaceuticals, Regeneron Pharmaceuticals, Madison Vaccines, Phosplatin Therapeutics, MacroGenics, RedHill Biopharma, Xencor and others.
• Metastatic Hormone Refractory Prostate Cancer Therapies- Enzalutamide, Patupilone, Prednisone, Docetaxel, Zactima (vandetanib), MDX-010, Denosumab, and others.
• Metastatic Hormone Refractory Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Hormone Refractory Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the Metastatic Hormone Refractory Prostate Cancer Treatment landscape in this detailed analysis @ https://www.delveinsight.com/sample-request/metastatic-hormone-refractory-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of Contents
1. Introduction
2. Executive Summary
3. Metastatic Hormone Refractory Prostate Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Hormone Refractory Prostate Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. PNT2002: Lantheus
9. Mid Stage Products (Phase II)
10. XL092: Exelixis
11. Early Stage Products (Phase I)
12. PF07248144: Pfizer
13. Preclinical and Discovery Stage Products
14. Inactive Products
15. Metastatic Hormone Refractory Prostate Cancer Key Companies
16. Metastatic Hormone Refractory Prostate Cancer Key Products
17. Metastatic Hormone Refractory Prostate Cancer- Unmet Needs
18. Metastatic Hormone Refractory Prostate Cancer- Market Drivers and Barriers
19. Metastatic Hormone Refractory Prostate Cancer- Future Perspectives and Conclusion
20. Metastatic Hormone Refractory Prostate Cancer Analyst Views
21. Metastatic Hormone Refractory Prostate Cancer Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.